10q10k10q10k.net
Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc.DNTHEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Dianthus Therapeutics is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for rare immunological and inflammatory diseases. It advances antibody-based candidates to address unmet needs of severe patients, operating primarily in the U.S. with global development partners.

Top Holders

Holder% OwnedSharesChangeAs of
FMR LLC14.97%
2.2M
—2023-11-13
BCLS Fund III Investments, LP9.99%
3.0M
—2024-02-02
Fairmount Funds Management LLC9.99%
3.0M
▲ +0.09pp2024-04-01
Avidity Partners Management LP9.90%
2.9M
flat2024-12-03
Viridian, LLC7.40%
1.1M
—2023-09-21
NOS. OF ABOVE PERSONS6.00%
1.7M
▼ -3.99pp2024-10-11
Venrock Healthcare Capital Partners III, L.P.5.90%
1.7M
—2024-11-14
BlackRock, Inc.5.60%
1.6M
flat2024-11-08
TCG Crossover GP II, LLC5.10%
1.5M
—2024-11-22
Andrew J. Schwab3.50%
1.0M
▼ -0.60pp2024-11-14
GV 2016, L.P.1.40%
208.7K
—2024-02-09
Third Rock Ventures IV, L.P.0.00%
14.8M
—2024-02-14
Citadel Advisors LLC0.00%
14.8M
—2024-02-14

Insider Transactions

Net 90d: −$28.77M · buys $0 / sells $28.77M
Range:
Action:
Role:
InsiderRoleAction
2026-04-09Ryan SavitzEVP, CFO & CBOOption exercise
8.2K
$17.88$147.0K
2026-04-09Ryan SavitzEVP, CFO & CBOSell (open market)
8.2K
$89.84$738.8K
2026-03-31Ryan SavitzEVP, CFO & CBOOption exercise
74.4K
$8.44$627.7K
2026-03-31Ryan SavitzEVP, CFO & CBOOption exercise
40.0K
$17.88$715.2K
2026-03-31Ryan SavitzEVP, CFO & CBOSell (open market)
1.4K
$78.33$108.9K
2026-03-31Ryan SavitzEVP, CFO & CBOSell (open market)
21.8K
$78.86$1.72M
2026-03-31Ryan SavitzEVP, CFO & CBOSell (open market)
1.5K
$80.25$119.2K
2026-03-31Ryan SavitzEVP, CFO & CBOSell (open market)
800
$81.36$65.1K
2026-03-31Ryan SavitzEVP, CFO & CBOSell (open market)
2.4K
$82.84$196.0K
2026-03-31Ryan SavitzEVP, CFO & CBOSell (open market)
59.8K
$83.90$5.02M
1–10 of 37
Page 1 / 4